Hansoh Pharmaceutical Group Co Limited/ADR
HNSPFDrugs in Pipeline
15
Phase 3 Programs
9
Upcoming Catalysts
2
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
HS-20093
Advanced Solid Tumor
Flumatinib 600mg qd
CML, CML-CP,MMR,TKI
Almonertinib
Non-small Cell Lung Cancer
HS-20117
Non-Squamous Non-Small Cell Lung Cancer
HS-10234
Chronic HBV Infection
HS-20094 injection
Overweight
Pegol-Sihematide
Chronic Kidney Diseases
Aumolertinib
Non-small Cell Lung Cancer
HS-20089
Ovarian Cancer
PEG-Tα1
Hepatitis B, Chronic
HS-10370
Advanced Solid Tumor
HS-20094 5mg
Type 2 Diabetes
iloperidone
Schizophrenia
HS-10374
Psoriatic Arthritis
HS-10516 + Lenvatinib
Advanced Clear Cell Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-20093 | Phase 3 | Advanced Solid Tumor | - | - |
Flumatinib 600mg qd | Phase 3 | CML, CML-CP,MMR,TKI | - | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
HS-20117 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
HS-10234 | Phase 3 | Chronic HBV Infection | - | - |
HS-20094 injection | Phase 3 | Overweight | - | - |
Pegol-Sihematide | Phase 3 | Chronic Kidney Diseases | - | - |
Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
HS-20089 | Phase 3 | Ovarian Cancer | - | - |
PEG-Tα1 | Phase 2 | Hepatitis B, Chronic | - | - |
HS-10370 | Phase 2 | Advanced Solid Tumor | - | - |
HS-20094 5mg | Phase 2 | Type 2 Diabetes | - | - |
iloperidone | Phase 2 | Schizophrenia | - | - |
HS-10374 | Phase 2 | Psoriatic Arthritis | - | - |
HS-10516 + Lenvatinib | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hansoh Pharmaceutical Group Co Limited/ADR's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Hansoh Pharmaceutical Group Co Limited/ADR's (HNSPF) pipeline across Phase 3, Phase 2. Its lead program is HS-20093 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hansoh Pharmaceutical Group Co Limited/ADR's next FDA catalyst?→
Hansoh Pharmaceutical Group Co Limited/ADR's (HNSPF) next tracked catalyst is a Phase 3 expected March 7, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HNSPF biotech catalysts?→
Add HNSPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hansoh Pharmaceutical Group Co Limited/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.